BCTXW
BriaCell Therapeutics Corp. Warrant
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$0.000
Máximo
$0.000
Mínimo
$0.000
Volume
0.02M
Fundamentos da empresa
Estatísticas de negociação
Notícias relacionadas
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ studies in metastatic breast cancer (MBC)Median Overall Survival of 17.3 months in Phase 2
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor
Bria-OTS has cleared its safety evaluation in the Phase 1/2 study monotherapy dosage settingPhase 1/2 study has now transitioned to dosing patients in combination with checkpoint inhibitor in metastatic breast cancer
BriaCell CEO Letter to Shareholders
Repeated positive recommendation from Data Safety Monitoring Board ("DSMB") of pivotal Phase 3 study for lead clinical candidate Bria-IMT™ in combination with checkpoint inhibitorBria-IMT has received Fast Track
Ações relacionadas
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.